EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END
/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical...
Thursday, December 12, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard...
/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the three recipients of its inaugural Health Equity Initiative. Based on the...
Wells Fargo highlighted the agreement’s $1.9 billion milestone potential, 40% U.S. profit-sharing terms, and double-digit royalties on ex-U.S. sales.
No income investor buys shares of a dividend-paying company expecting that it will suspend its distributions at some point. Quite the contrary, dividend investors want those payouts to keep going and growing...
Novartis NVS announced that the European Commission (“EC”) has approved its breast cancer drug Kisqali (ribociclib) for a broad population.The EC has approved Kisqali in combination with an aromatase...
This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia drug Hympavzi (marstacimab). AstraZeneca’s AZN Tagrisso was recommended...
Novartis NVS announced that it has increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with...
/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTO™ (lutetium (177Lu) vipivotide...